European Leukemia Trial Registry
Trial: ALL GMALL MabCampath

More Details
Title abCampath in refractory/relapsed/primary therapy failure in ALL and lymphoblastic lymphoma with MRD
Scientific Title German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure
Short Title ALL GMALL MabCampath
Trialgroup GMALL
Type of Trial multicentric
Disease Acute lymphoblastic leukemia(ALL) All subtypes
Age >= 18 years
Status Closed
Start of Recruitment 01.02.2004
Leader Hoelzer, Prof. Dr. med., Dieter
Contactperson

Study Physician
Gökbuget, Dr. med., Nicola
Tel: +49 (0)69 6301-6366
Fax: +49 (0)69 6301- 7463
Email: goekbuget@em.uni-frankfurt.de

Study Centre
Koy-Redemann, Regina
Tel: +49 (0)69 6301-87146
Fax: +49 (0)69 6301-7463
Email: koy-redemann@em.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
Diagnostics

MRD-Analysis
Hämatologie Labor Kiel

created 07.07.2006 Anja Hellenbrecht
changed 03.11.2014 Sina Hehn
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org